Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozurdex versus Avastin for diabetic macular oedema in Indigenous Australian adults undergoing or having undergone cataract surgery
ACTRN12618000202268Phase 3Active, not recruiting
- Sponsor
- Lions Eye Institute
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of ozurdex and bevacizumab in diabetic macular edema (DME) (2 arms), sponsored by Lions Eye Institute. Primary endpoint: Mean change in best-corrected visual acuity. Started Feb 2017; status: active, not recruiting.
02
Drugs
ozurdexbevacizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ACTRN12618000202268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000202268.